Arterielle Hypertonie – Eine Übersicht für den ärztlichen Alltag

Felicitas E. Hengel; Christian Sommer; Ulrich Wenzel

doi:10.1055/a-1835-8049

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie, Table of Contents

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie 2022; 9(03): 207-221
DOI: 10.1055/a-1835-8049

CME-Fortbildung

Arterielle Hypertonie – Eine Übersicht für den ärztlichen Alltag

Felicitas E. Hengel

,

Christian Sommer

,

Ulrich Wenzel

Abstract

Die immense Bedeutung des Bluthochdrucks erwächst nicht nur aus der Häufigkeit der Erkrankung, sondern besonders aus dem mit der Erkrankung einhergehenden erhöhten kardiovaskulären Risiko. Bis zu 10 Millionen Todesfälle pro Jahr gehen weltweit auf erhöhten Blutdruck zurück. Diese Übersicht über die möglichen Ursachen, Diagnostik und leitliniengerechte Therapie soll helfen, die Versorgung von Patienten mit arterieller Hypertonie zu verbessern.

Full Text

References

Literatur
1 Neuhauser H, Kuhnert R, Born S. 12-Month prevalence of hypertension in Germany. Journal of Health Monitoring 2017; 2: 51-57
2 Chow CK, Teo KK, Rangarajan S. et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-968
3 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
4 Forouzanfar MH, Liu P, Roth GA. et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317: 165-182
5 Banegas JR, Lopez-Garcia E, Dallongeville J. et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32: 2143-2152
6 Wenzel U. [The National High Blood Pressure Strategy of the German Hypertension League]. MMW Fortschr Med 2020; 162: 62-65
7 Conroy RM, Pyörälä K, Fitzgerald AP. et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003
8 Brunstrom M, Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178: 28-36
9 Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. . J Hypertens 2014; 32: 2285-2295
10 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: e13-e115
11 Stergiou GS, Palatini P, Parati G. et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021; 39: 1293-1302
12 Clark CE, Taylor RS, Shore AC. et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. The Lancet 2012; 379: 905-914
13 Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res 2015; 116: 1034-1045
14 Verdecchia P, Angeli F, Mazzotta G. et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012; 60: 34-42
15 Ohkubo T, Imai Y, Tsuji I. et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. . Am J Hypertens 1997; 10: 1201-1207
16 Cuspidi C, Sala C, Tadic M. et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: An updated review. The Journal of Clinical Hypertension 2017; 19: 713-721
17 Sherwood A, Steffen PR, Blumenthal JA. et al. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hypertens 2002; 15: 111-118
18 Kidney Disease: Improving Global Outcomes Blood Pressure Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99: S1-S87
19 He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2013;
20 Mattes RD, Donnelly D. Relative contributions of dietary sodium sources. J Am Coll Nutr 1991; 10: 383-393
21 Borghi C, Tsioufis K, Agabiti-Rosei E. et al. Nutraceuticals and blood pressure control: a European Society of Hypertension position document. J Hypertens 2020; 38: 799-812
22 Wald DS, Law M, Morris JK. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300
23 Law MR, Wald NJ, Morris JK. et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Bmj 2003; 326: 1427
24 Yusuf S, Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
25 BfArM. Hydrochlorothiazid – Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. Rote-Hand-Brief. Bundesinstitut für Arzneimittel und Medizinprodukte 2018. Im Internet (Stand: 16.01.2022): https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhbhydrochlorothiazid.html
26 Unger T, Borghi C, Charchar F. et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens 2020; 38: 982-1004
27 Ettehad D, Emdin CA, Kiran A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet 2016; 387: 957-967
28 Nadeem S, Hashmat S, Defreitas MJ. et al. Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report. J Pediatr 2015; 167: 881-885
29 Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen?. Eur Heart J 2014; 35: 1245-1254
30 Persu A, Giavarini A, Touze E. et al. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014; 32: 1367-1378
31 Courand PY, Dinic M, Lorthioir A. et al. Resistant Hypertension and Atherosclerotic Renal Artery Stenosis: Effects of Angioplasty on Ambulatory Blood Pressure. A Retrospective Uncontrolled Single-Center Study. . Hypertension 2019; 74: 1516-1523
32 Berra E, Azizi M, Capron A. et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension 2016; 68: 297-306
33 Lane D, Lawson A, Burns A. et al. Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension 2022; 79: 12-23
34 Azizi M, Schmieder RE, Mahfoud F. et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCEHTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. The Lancet 2018; 391: 2335-2345
35 Böhm M, Kario K, Kandzari DE. et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet 2020; 395: 1444-1451
36 Kandzari DE, Böhm M, Mahfoud F. et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet 2018; 391: 2346-2355
37 Azizi M, Sanghvi K, Saxena M. et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, shamcontrolled trial. Lancet 2021; 397: 2476-2486
38 Mahfoud F, Schlaich MP, Lobo MD. Device Therapy of Hypertension. Circ Res 2021; 128: 1080-1099
39 Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655
40 Uijl E, Mirabito Colafella KM, Sun Y. et al. Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. Hypertension 2019; 73: 1249-1257
41 Ray KK, Landmesser U, Leiter LA. et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017; 376: 1430-1440
42 Huang SA, Taubel J, Fiore G. et al. Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults. Glasgow, UK: Joint Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH); 2021